Show an ad over header. AMP

I am the second

Sanofi, GSK COVID vaccine shows strong immune response in phase 2 trials

Sanofi and GSK announcedthis morning their COVID-19 vaccine candidate demonstrated a strong immune response in adults in a phase 2 clinical trial.

Why it matters: Sanofi and GSK say their recombinant protein-based vaccine candidate could ultimately serve as a universal COVID-19 vaccine booster, able to boost immunity regardless of the vaccination first received.

Keep reading... Show less

Related Articles

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories